

Aurobindo gets USFDA Nod for Generic Migraine Drug



NEW DELHI: Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan tablets in strengths of 2.5 mg and 5 mg, Aurobindo Pharma said in a regulatory filing. "This product is expected to be launched in second quarter of FY16-17," it added. The product is the generic equivalent of IPR Pharmaceuticals' Zomig, which is used in the treatment of migraine in adults. "The approved product has an estimated market size of \$46.7 million for the 12 months ending March 2016 according to IMS," Aurobindo Pharma said.

Company